The Lynx Group

Solid Tumors

San Francisco, CA—A second study adds to the body of evidence that including a luteinizing hormone-releasing hormone (LHRH) agonist with chemotherapy as treatment for breast cancer increases a younger woman’s likelihood of becoming pregnant.
Read Article

San Francisco, CA—Preoperative breast magnetic resonance imaging (MRI) failed to influence clinical management in any subgroup of 257 patients with breast cancer, according to the results of a retrospective review that led one cancer center to discontinue the practice.
Read Article

San Francisco, CA—A new GP2 peptide vaccine was safe and reduced the rate of breast cancer recurrence in women with high-risk breast cancer in a phase 2 clinical trial.
Read Article

Toronto, Ontario—New laser-based imaging technology differentiates malignant melanoma from other cancerous and benign skin lesions, according to a preliminary study presented at the 2014 Canadian Dermatology Association annual conference.
Read Article

Chicago, IL—When added to chemotherapy (ie, docetaxel), the new monoclonal antibody ramucirumab improved overall survival (OS) compared with chemotherapy alone in patients with stage IV non–small-cell lung cancer (NSCLC), according to phase 3 trial results presented at the 2014 American Society of Clinical Oncology meeting.
Read Article

Chicago, IL— Necitumumab, a human immunoglobulin G1 anti-EGFR monoclonal antibody, added to standard chemotherapy significantly improved survival compared with chemotherapy alone as first-line treatment of patients with stage IV non–small-cell lung cancer (NSCLC) of squamous histology.
Read Article

Toronto, Ontario—Going to more than 10 indoor tanning sessions over a person’s lifetime is associated with a 34% increased risk of developing melanoma, according to a new meta-analysis presented at the 2014 Canadian Dermatology Association annual meeting.
Read Article

Chicago, IL—The upfront addition of docetaxel to androgen deprivation therapy (ADT) adds more than 1 year to overall survival (OS) compared with ADT alone in men with newly diagnosed hormone-sensitive prostate cancer, according to findings from a phase 3 study presented at the 2014 American Society of Clinical Oncology meeting.
Read Article

Chicago, IL—Adjuvant exemestane is more effective at preventing breast cancer recurrences than tamoxifen when given with ovarian function suppression (OFS) in young women with hormone receptor–positive early breast cancer, reported Olivia Pagani, MD, Clinical Director, Breast Unit, Oncology Institute of Southern Switzerland, Bellinzona, at the 2014 American Society of Clinical Oncology meeting.
Read Article

Approximately 15% to 20% of patients with breast cancer have HER2-positive disease. Brain metastases are relatively common in patients with HER2-positive metastatic breast cancer, with up to 50% of patients developing metastases over time.
Read Article

Page 10 of 16

Subscribe to
Value-Based Cancer Care

Stay up to date with personalized medicine by subscribing to receive the free VBCC print publication or weekly e‑Newsletter.

I'd like to receive: